RxDoctor Payments Data

Kerollos Askander, MD

Family Medicine · Howell, NJNPI 1861984924

Payments from drug & device makers

$592in general payments, 2019–2025

Across 26 payments — averaging $22.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$122
  • GSK$112
  • Lilly USA, LLC$100
  • Bayer$68
  • AstraZeneca$62
  • Novo Nordisk$42
  • plus $85 from 4 others

What the payments were for

  • Food & beverage$592100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$592 in reported general payments places this provider in the 55th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$45,577
Medicare patients
122
Services billed
388

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol40$45,070
TrulicityDulaglutide35$43,359
MounjaroTirzepatide35$40,989
OzempicSemaglutide11$12,644
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,097
Humulin 70/30 KwikpenInsulin Nph Hum/Reg Insulin Hm19$2,722
Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro14$2,249
Rosuvastatin Calcium121$2,218
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$1,899
Albuterol Sulfate HfaAlbuterol Sulfate62$1,606
Atorvastatin Calcium138$1,545
Tresiba Flextouch U-100Insulin Degludec14$1,359
Wixela InhubFluticasone Propion/Salmeterol12$1,146
Levothyroxine Sodium107$827
Diclofenac Sodium23$790

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$100$84,34770 claims
AstraZenecaFarxiga$62$45,07040 claims
Novo NordiskOzempic$42$12,64411 claims
GSKTrelegy Ellipta$112$7,09711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Howell

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →